Sparfloxacin (cas 111542-93-9)

Add time:09/01/2019    Source:sciencedirect.com

Sparfloxacin is a third generation, broad spectrum fluoroquinolone antibiotic. Its main advantages over older fluoroquinolones are improved activity against gram-positive pathogens and a long half-life that allows for once a day dosing. In comparison to other fluoroquinolones, sparfloxacin has enhanced in vitro activity, especially against gram-positive cocci and anaerobes. Sparfloxacin is effective for the treatment of adults with community acquired pneumonia and acute bacterial exacerbations of chronic bronchitis caused by susceptible organisms and sinusitis. While its adverse effects are generally similar to other fluoroquinolones, it is more phototoxic. Sparfloxacin was withdrawn from the market by the manufacturer in 2001.

We also recommend Trading Suppliers and Manufacturers of Sparfloxacin (cas 111542-93-9). Pls Click Website Link as below: cas 111542-93-9 suppliers

Prev:New perspective on the metabolism of AD-1 in vivo: Characterization of a series of dammarane-type derivatives with novel metabolic sites and anticancer mechanisms of active oleanane-type metabolites
Next:Combined experimental and theoretical studies on the diorganotin(IV) complexes of Sparfloxacin (cas 111542-93-9): Synthesis, spectroscopic and DFT studies, and biological activity)